Global Post Herpetic Neuralgia Treatment Market

Post Herpetic Neuralgia Treatment Comprehensive Study by Type (Patches (Capsaicin Skin Patches and Lidocaine Skin Patches), Drugs, Opioids), Application (Hospitals, Clinics, Others), Distribution Channel (Hospital Pharmacies, Drug Stores, Retail Pharmacies, Others) Players and Region - Global Market Outlook to 2026

Post Herpetic Neuralgia Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Post Herpetic Neuralgia Treatment Market Scope
Postherpetic neuralgia affects the nerve fibers and skin. PHN is nerve pain that persists for more than 30 days after the reactivation of herpes zoster. The nerve pain is a result of damage to the peripheral nerve. The postherpetic neuralgia treatment market is expected to grow in the future due to an increase in the prevalence of postherpetic neuralgia and availability of advancements in treatment Techniques.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to avail competitive advantage through combined collaborations. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Post Herpetic Neuralgia Treatment market throughout the predicted period.

Pfizer (United States), Teva Pharmaceutical Industries Ltd (Isreal), Mylan N.V. (United States), Endo (Ireland), Daiichi Sankyo (Japan), Acorda Therapeutics (United States), Purdue Pharma L.P (United States), Teikoku Pharma USA, Inc.(United States) and Janssen Pharmaceuticals, Inc. (Belgium) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
The study have segmented the market of Global Post Herpetic Neuralgia Treatment market by Type (Patches (Capsaicin Skin Patches and Lidocaine Skin Patches), Drugs and Opioids), by Application (Hospitals, Clinics and Others) and Region with country level break-up.

On the basis of geography, the market of Post Herpetic Neuralgia Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Market Trend
  • Advancements in Treatment Techniques for Post Herpetic Neuralgia

Market Drivers
  • Increase in the Prevalence of Postherpetic Neuralgia
  • Rising Geriatrics Population Across the World

Opportunities
  • Development of Health Care Infrastructure in Developed as well as Developing Countries
  • Government Initiatives to Spread Awareness regarding Post-herpetic Neuralgia Treatment Products

Restraints
  • High Cost of Neuropathy Pain Treatment
  • Lack of Health Infrastructure and Budgets in Emerging Countries

Challenges
  • Side Effects of Treatment such as Sedation, Dry Mouth, Constipation, and Urinary Retention, and Orthostatic Hypotension


Key Target Audience
Post Herpetic Neuralgia Treatment Providers, Healthcare Industry, Research Institutes, Government Agencies, Medical Research Laboratories and Others

Report Objectives / Segmentation Covered

By Type
  • Patches (Capsaicin Skin Patches and Lidocaine Skin Patches)
  • Drugs
  • Opioids
By Application
  • Hospitals
  • Clinics
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the Prevalence of Postherpetic Neuralgia
      • 3.2.2. Rising Geriatrics Population Across the World
    • 3.3. Market Challenges
      • 3.3.1. Side Effects of Treatment such as Sedation, Dry Mouth, Constipation, and Urinary Retention, and Orthostatic Hypotension
    • 3.4. Market Trends
      • 3.4.1. Advancements in Treatment Techniques for Post Herpetic Neuralgia
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Post Herpetic Neuralgia Treatment, by Type, Application, Distribution Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Post Herpetic Neuralgia Treatment (Value)
      • 5.2.1. Global Post Herpetic Neuralgia Treatment by: Type (Value)
        • 5.2.1.1. Patches (Capsaicin Skin Patches and Lidocaine Skin Patches)
        • 5.2.1.2. Drugs
        • 5.2.1.3. Opioids
      • 5.2.2. Global Post Herpetic Neuralgia Treatment by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Post Herpetic Neuralgia Treatment by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Drug Stores
        • 5.2.3.3. Retail Pharmacies
        • 5.2.3.4. Others
      • 5.2.4. Global Post Herpetic Neuralgia Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Post Herpetic Neuralgia Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Teva Pharmaceutical Industries Ltd (Isreal)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mylan N.V. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Endo (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Daiichi Sankyo (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Acorda Therapeutics (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Purdue Pharma L.P (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teikoku Pharma USA, Inc.(United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Janssen Pharmaceuticals, Inc. (Belgium)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Post Herpetic Neuralgia Treatment Sale, by Type, Application, Distribution Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Post Herpetic Neuralgia Treatment (Value)
      • 7.2.1. Global Post Herpetic Neuralgia Treatment by: Type (Value)
        • 7.2.1.1. Patches (Capsaicin Skin Patches and Lidocaine Skin Patches)
        • 7.2.1.2. Drugs
        • 7.2.1.3. Opioids
      • 7.2.2. Global Post Herpetic Neuralgia Treatment by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Post Herpetic Neuralgia Treatment by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Drug Stores
        • 7.2.3.3. Retail Pharmacies
        • 7.2.3.4. Others
      • 7.2.4. Global Post Herpetic Neuralgia Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Post Herpetic Neuralgia Treatment: by Type(USD Million)
  • Table 2. Post Herpetic Neuralgia Treatment Patches (Capsaicin Skin Patches and Lidocaine Skin Patches) , by Region USD Million (2015-2020)
  • Table 3. Post Herpetic Neuralgia Treatment Drugs , by Region USD Million (2015-2020)
  • Table 4. Post Herpetic Neuralgia Treatment Opioids , by Region USD Million (2015-2020)
  • Table 5. Post Herpetic Neuralgia Treatment: by Application(USD Million)
  • Table 6. Post Herpetic Neuralgia Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 7. Post Herpetic Neuralgia Treatment Clinics , by Region USD Million (2015-2020)
  • Table 8. Post Herpetic Neuralgia Treatment Others , by Region USD Million (2015-2020)
  • Table 9. Post Herpetic Neuralgia Treatment: by Distribution Channel(USD Million)
  • Table 10. Post Herpetic Neuralgia Treatment Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 11. Post Herpetic Neuralgia Treatment Drug Stores , by Region USD Million (2015-2020)
  • Table 12. Post Herpetic Neuralgia Treatment Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 13. Post Herpetic Neuralgia Treatment Others , by Region USD Million (2015-2020)
  • Table 14. South America Post Herpetic Neuralgia Treatment, by Country USD Million (2015-2020)
  • Table 15. South America Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 16. South America Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 17. South America Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 18. Brazil Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 19. Brazil Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 20. Brazil Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 21. Argentina Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 22. Argentina Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 23. Argentina Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 24. Rest of South America Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 25. Rest of South America Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 26. Rest of South America Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 27. Asia Pacific Post Herpetic Neuralgia Treatment, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 29. Asia Pacific Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 30. Asia Pacific Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 31. China Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 32. China Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 33. China Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 34. Japan Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 35. Japan Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 36. Japan Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 37. India Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 38. India Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 39. India Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 40. South Korea Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 41. South Korea Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 42. South Korea Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 43. Taiwan Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 44. Taiwan Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 45. Taiwan Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 46. Australia Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 47. Australia Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 48. Australia Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 52. Europe Post Herpetic Neuralgia Treatment, by Country USD Million (2015-2020)
  • Table 53. Europe Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 54. Europe Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 55. Europe Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 56. Germany Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 57. Germany Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 58. Germany Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 59. France Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 60. France Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 61. France Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 62. Italy Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 63. Italy Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 64. Italy Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 65. United Kingdom Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 66. United Kingdom Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 67. United Kingdom Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 68. Netherlands Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 69. Netherlands Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 70. Netherlands Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 71. Rest of Europe Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 72. Rest of Europe Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 73. Rest of Europe Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 74. MEA Post Herpetic Neuralgia Treatment, by Country USD Million (2015-2020)
  • Table 75. MEA Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 76. MEA Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 77. MEA Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 78. Middle East Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 79. Middle East Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 80. Middle East Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 81. Africa Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 82. Africa Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 83. Africa Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 84. North America Post Herpetic Neuralgia Treatment, by Country USD Million (2015-2020)
  • Table 85. North America Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 86. North America Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 87. North America Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 88. United States Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 89. United States Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 90. United States Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 91. Canada Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 92. Canada Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 93. Canada Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 94. Mexico Post Herpetic Neuralgia Treatment, by Type USD Million (2015-2020)
  • Table 95. Mexico Post Herpetic Neuralgia Treatment, by Application USD Million (2015-2020)
  • Table 96. Mexico Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Post Herpetic Neuralgia Treatment: by Type(USD Million)
  • Table 107. Post Herpetic Neuralgia Treatment Patches (Capsaicin Skin Patches and Lidocaine Skin Patches) , by Region USD Million (2021-2026)
  • Table 108. Post Herpetic Neuralgia Treatment Drugs , by Region USD Million (2021-2026)
  • Table 109. Post Herpetic Neuralgia Treatment Opioids , by Region USD Million (2021-2026)
  • Table 110. Post Herpetic Neuralgia Treatment: by Application(USD Million)
  • Table 111. Post Herpetic Neuralgia Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 112. Post Herpetic Neuralgia Treatment Clinics , by Region USD Million (2021-2026)
  • Table 113. Post Herpetic Neuralgia Treatment Others , by Region USD Million (2021-2026)
  • Table 114. Post Herpetic Neuralgia Treatment: by Distribution Channel(USD Million)
  • Table 115. Post Herpetic Neuralgia Treatment Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 116. Post Herpetic Neuralgia Treatment Drug Stores , by Region USD Million (2021-2026)
  • Table 117. Post Herpetic Neuralgia Treatment Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 118. Post Herpetic Neuralgia Treatment Others , by Region USD Million (2021-2026)
  • Table 119. South America Post Herpetic Neuralgia Treatment, by Country USD Million (2021-2026)
  • Table 120. South America Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 121. South America Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 122. South America Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 123. Brazil Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 124. Brazil Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 125. Brazil Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 126. Argentina Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 127. Argentina Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 128. Argentina Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 129. Rest of South America Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 130. Rest of South America Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 131. Rest of South America Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 132. Asia Pacific Post Herpetic Neuralgia Treatment, by Country USD Million (2021-2026)
  • Table 133. Asia Pacific Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 134. Asia Pacific Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 135. Asia Pacific Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 136. China Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 137. China Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 138. China Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 139. Japan Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 140. Japan Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 141. Japan Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 142. India Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 143. India Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 144. India Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 145. South Korea Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 146. South Korea Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 147. South Korea Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 148. Taiwan Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 149. Taiwan Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 150. Taiwan Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 151. Australia Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 152. Australia Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 153. Australia Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 154. Rest of Asia-Pacific Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 155. Rest of Asia-Pacific Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 156. Rest of Asia-Pacific Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 157. Europe Post Herpetic Neuralgia Treatment, by Country USD Million (2021-2026)
  • Table 158. Europe Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 159. Europe Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 160. Europe Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 161. Germany Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 162. Germany Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 163. Germany Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 164. France Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 165. France Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 166. France Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 167. Italy Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 168. Italy Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 169. Italy Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 170. United Kingdom Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 171. United Kingdom Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 172. United Kingdom Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 173. Netherlands Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 174. Netherlands Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 175. Netherlands Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 176. Rest of Europe Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 177. Rest of Europe Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 178. Rest of Europe Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 179. MEA Post Herpetic Neuralgia Treatment, by Country USD Million (2021-2026)
  • Table 180. MEA Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 181. MEA Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 182. MEA Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 183. Middle East Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 184. Middle East Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 185. Middle East Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 186. Africa Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 187. Africa Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 188. Africa Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 189. North America Post Herpetic Neuralgia Treatment, by Country USD Million (2021-2026)
  • Table 190. North America Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 191. North America Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 192. North America Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 193. United States Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 194. United States Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 195. United States Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 196. Canada Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 197. Canada Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 198. Canada Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 199. Mexico Post Herpetic Neuralgia Treatment, by Type USD Million (2021-2026)
  • Table 200. Mexico Post Herpetic Neuralgia Treatment, by Application USD Million (2021-2026)
  • Table 201. Mexico Post Herpetic Neuralgia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 202. Research Programs/Design for This Report
  • Table 203. Key Data Information from Secondary Sources
  • Table 204. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Post Herpetic Neuralgia Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Post Herpetic Neuralgia Treatment: by Application USD Million (2015-2020)
  • Figure 6. Global Post Herpetic Neuralgia Treatment: by Distribution Channel USD Million (2015-2020)
  • Figure 7. South America Post Herpetic Neuralgia Treatment Share (%), by Country
  • Figure 8. Asia Pacific Post Herpetic Neuralgia Treatment Share (%), by Country
  • Figure 9. Europe Post Herpetic Neuralgia Treatment Share (%), by Country
  • Figure 10. MEA Post Herpetic Neuralgia Treatment Share (%), by Country
  • Figure 11. North America Post Herpetic Neuralgia Treatment Share (%), by Country
  • Figure 12. Global Post Herpetic Neuralgia Treatment share by Players 2020 (%)
  • Figure 13. Global Post Herpetic Neuralgia Treatment share by Players (Top 3) 2020(%)
  • Figure 14. Global Post Herpetic Neuralgia Treatment share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 17. Pfizer (United States) Revenue: by Geography 2020
  • Figure 18. Teva Pharmaceutical Industries Ltd (Isreal) Revenue, Net Income and Gross profit
  • Figure 19. Teva Pharmaceutical Industries Ltd (Isreal) Revenue: by Geography 2020
  • Figure 20. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Mylan N.V. (United States) Revenue: by Geography 2020
  • Figure 22. Endo (Ireland) Revenue, Net Income and Gross profit
  • Figure 23. Endo (Ireland) Revenue: by Geography 2020
  • Figure 24. Daiichi Sankyo (Japan) Revenue, Net Income and Gross profit
  • Figure 25. Daiichi Sankyo (Japan) Revenue: by Geography 2020
  • Figure 26. Acorda Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 27. Acorda Therapeutics (United States) Revenue: by Geography 2020
  • Figure 28. Purdue Pharma L.P (United States) Revenue, Net Income and Gross profit
  • Figure 29. Purdue Pharma L.P (United States) Revenue: by Geography 2020
  • Figure 30. Teikoku Pharma USA, Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 31. Teikoku Pharma USA, Inc.(United States) Revenue: by Geography 2020
  • Figure 32. Janssen Pharmaceuticals, Inc. (Belgium) Revenue, Net Income and Gross profit
  • Figure 33. Janssen Pharmaceuticals, Inc. (Belgium) Revenue: by Geography 2020
  • Figure 34. Global Post Herpetic Neuralgia Treatment: by Type USD Million (2021-2026)
  • Figure 35. Global Post Herpetic Neuralgia Treatment: by Application USD Million (2021-2026)
  • Figure 36. Global Post Herpetic Neuralgia Treatment: by Distribution Channel USD Million (2021-2026)
  • Figure 37. South America Post Herpetic Neuralgia Treatment Share (%), by Country
  • Figure 38. Asia Pacific Post Herpetic Neuralgia Treatment Share (%), by Country
  • Figure 39. Europe Post Herpetic Neuralgia Treatment Share (%), by Country
  • Figure 40. MEA Post Herpetic Neuralgia Treatment Share (%), by Country
  • Figure 41. North America Post Herpetic Neuralgia Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Teva Pharmaceutical Industries Ltd (Isreal)
  • Mylan N.V. (United States)
  • Endo (Ireland)
  • Daiichi Sankyo (Japan)
  • Acorda Therapeutics (United States)
  • Purdue Pharma L.P (United States)
  • Teikoku Pharma USA, Inc.(United States)
  • Janssen Pharmaceuticals, Inc. (Belgium)
Select User Access Type

Key Highlights of Report


Aug 2021 214 Pages 76 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Post Herpetic Neuralgia Treatment Market Quantitative research analysis
Global Post Herpetic Neuralgia Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Post Herpetic Neuralgia Treatment study can be customized to meet your requirements. The market size breakdown by type [Patches (Capsaicin Skin Patches and Lidocaine Skin Patches), Drugs and Opioids], by end use application [Hospitals, Clinics and Others].
The Post Herpetic Neuralgia Treatment Market is gaining popularity and expected to see strong valuation by 2026.
According to AMA, the Global Post Herpetic Neuralgia Treatment market is expected to see growth rate of %.

Know More About Global Post Herpetic Neuralgia Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Dried Blood Spot Collection Cards Comprehensive Study by Type (Ahlstrom 226, Whatman 903, Flinders Technology Associates (FTA), Others), Application (Forensics, Infectious Disease Testing, Newborn Sc...
$ 3650
Deep Wrinkle Fillers Comprehensive Study by Type (Hyaluronic Acid, Synthetic, Collagen, Autologous), Application (Hospital, Dermatology Clinics, Beauty Salon), Form (Cream, Injectable) Players and Re...
$ 3500
Prescription Dermatology Therapeutics Comprehensive Study by Type (Topical Corticosteroids, Retinoids, Biologics, Calcineurin Inhibitors, Antihistamines, Hormone Therapy), Application (Psoriasis, Ato...
$ 3750
Desensitization Comprehensive Study by Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy), Application (Allergic Rhinitis, Allergic Asthma, Other), End-users (Hospitals, Clinics, Others) Pla...
$ 3500
Tissue Regeneration Comprehensive Study by Application (Cardiovascular, Oncology, Dermatology, Orthopedic, Neurology, Ophthalmology, Others), Raw Material (Synthetic, Genetically Modified, Biological...
$ 3750
Dilated Cardiomyopathy Comprehensive Study by Drugs (Angiotensin-Converting Enzyme (ACE) Inhibitors, Beta Blockers, Aldosterone Antagonists, Digitalis, Angiotensin II Receptor Blockers, Anticoagulant...
$ 3750